Negotiations and the preliminary\u00a0merger process have taken place throughout the year, with institutional support from\u00a0ACCI\u00d3, the Catalan government agency that promotes clusters, and legal guidance from\u00a0RCD.<\/p>\n
CataloniaBio & HealthTech\u00a0now represents more than 170 companies, as well as collaborating stakeholders such as hospitals, research centres and universities that are leaders in R&D in biomedicine.The profile of member companies ranges from microenterprises to SMEs and large corporations developing products (drugs medical devices, diagnostic tests, etc.), scientific services, non-scientific services and knowledge generators.<\/p>\n
In Catalonia, which has become a global benchmark in medicine and clinical research in recent years, two main sectors of innovation are being consolidated:\u00a0ICT and health. Thanks to this integration, the new association will represent the sector in a more transversal way,\u00a0promoting the convergence of biopharma, medical technology (MedTech) and digital health, which were previously seen as parallel paths, encouraging synergies and collaborations, and building a significant critical mass to tackle future challenges.<\/p>\n
\u201cWe\u2019re in a time of global change and we have to be aware of it and move towards it. Joining forces with the HealthTech Cluster fits perfectly with the strategy we established in 2014 with the new board for what CataloniaBio should be. We were looking for growth, visibility and projection of the biomedical business fabric,\u201d explained Ignasi Biosca, outgoing president of CataloniaBio and managing director of\u00a0Reig Jofre.<\/p>\n
Seven\u00a0strategic lines\u00a0have been established: internal and external networking, innovation and technology transfer, international alliances, investment and funding, talent management, regulatory framework and communication.<\/p>\n
\u201cWe\u2019re becoming a benchmark in innovation,\u201d explained Albert Gallart, outgoing president of the HealthTech Cluster and CEO of\u00a0Grupo Pulso. \u201cThis isn\u2019t the end of a project, it\u2019s the beginning of a bigger one. It is a tool that will depend on how we use it as members. With this merger, we will get out ahead of other countries with healthcare ecosystems,\u201d said Albert Giralt, outgoing vice-president and general manager of the HealthTech Cluster and general manager of\u00a0Avinent.<\/p>\n
Clara Camp\u00e0s, outgoing vice-president of CataloniaBio and director of Strategy and Development at\u00a0Kern Pharma, highlighted \u201cthe great motivation behind the launch of this process and the opportunities it will bring from here on out.\u201d<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"
A new era for the\u00a0CataloniaBio<\/a>\u00a0association of companies and the\u00a0HealthTech Cluster<\/a>. Members of the two organisations unanimously passed the motion to merge\u00a0under the brand CataloniaBio & HealthTech\u00a0at their respective extraordinary general meetings held in Barcelona yesterday.The headquarters will be located at the\u00a0Barcelona Science Park.\u00a0It will promote the convergence of biopharma, MedTech and digital health companies to boost competitiveness and address unmet medical needs\u00a0<\/p>\n \u00a0<\/p>\n","protected":false},"author":1,"featured_media":53131,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-49491","post","type-post","status-publish","format-standard","has-post-thumbnail","category-uncategorized"],"acf":[],"yoast_head":"\n